comprehensive -WSS

comprehensive

author：knowledge 2025-09-03 15:23:35 - browse：92

Sammy Kimball for STAT

Can unicorns survive without data? Did biotech get over its skis? And what is going on at Biogen?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen’s boardroom scandal has roiled a company that was supposed to be entering a new era.

For more on what we cover, here’s the Laronde story; here’s the latest on Biogen; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Peter Hotez and the public health issue of online harassment
Next article： How should state employee insurance handle Wegovy?

WSS

There’s no way to know how good AI health technologies are

STAT Readout: Today's biotech news includes Sana and Amylyx

Intercept Pharmaceuticals sells itself for less than $1 billion

Humana CEO Bruce Broussard to step down in 2024

Akero's treatment for NASH falls short in cirrhosis study

What the Wegovy shortage looks like for doctors — and for patients

leisure time

comprehensive

focus

Moonlake's readout produced a cash windfall. Risks remain

How clinical AI models' predictive power can degrade over time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What the Wegovy shortage looks like for doctors — and for patients

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Researchers use wearables data and AI to predict preterm birth risk

Sports medicine is finally prioritizing gender equality

After a drawn out lobbying fight, ARPA

How to save PrEP access — and even expand it

WHO recommends dropping component of many flu vaccines

hotspot

How doctors and nurses shape Google's AI

Massive project maps cells in human brain in unprecedented detail

European regulators recommend Amylyx's ALS drug be rejected

Peter Marks talks Operation Warp Speed for Rare Diseases

Health tech startups drop sharply from 2021 highs

How the Dana

focus

focus

entertainment

entertainment